FDA Commissioner Robert Califf told lawmakers he’s ready to work with them to bring more drug manufacturing to the US and ...
Corner Therapeutics' $54 million Series A will be used to bring new immunotherapies for cancer and infectious diseases into ...
Sanofi is overhauling its US commercial operations for its vaccines and will cut an undisclosed number of jobs, the company ...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and ...
A new startup aims to challenge Novo Nordisk and Eli Lilly's duopoly atop today's market for obesity drugs. The startup ...
Trust in the pharma industry is up among consumers, but slipped for the biotech sector in an unusual flip of sentiment about ...
As it waits for its acquisition by AbbVie to finalize, Cerevel reported a Phase 3 win for one of its programs in Parkinson’s ...
Viatris named Corinne Le Goff as its new chief commercial officer on Monday. Le Goff comes from Imunon where she was CEO, but ...
Pathios Therapeutics drew in $25 million for the first close of a Series B raise that should help the UK biotech test its ...
Sanofi's oncology pruning will lead to the evaporation of an estimated $3 billion in potential biobucks for partner IGM ...
Histogen files for Chapter 11 bankruptcy: The biotech, which stopped work in September, filed a petition with the US Bankruptcy Court for the Southern District of California. Its next steps include ...
Roche’s Genentech said that Alecensa scored a label expansion from the FDA, with the drug now approved as an adjuvant treatment following tumor resection in patients with ALK-positive non-small cell ...